Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT1 | Q96EB6 | 7/20 | 0.33 |
| ▸ | CA1 | P00915 | 3/20 | 0.32 |
| ▸ | CA2 | P00918 | 3/20 | 0.32 |
| ▸ | SIRT2 | Q8IXJ6 | 7/20 | 0.31 |
| ▸ | SIRT3 | Q9NTG7 | 3/20 | 0.30 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.30 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12721099 | 0.86 | SIRT5 (0.39) | SIRT1CA1CA2SIRT5 | |
| SCHEMBL10026185 | 0.77 | AKT1 (0.39) | SIRT1CA1CA2SIRT2SIRT3 | |
| SCHEMBL14016183 | 0.74 | AKT1 (0.40) | SIRT1CA1CA2SIRT2SIRT3 | |
| SCHEMBL10167189 | 0.74 | AKT1 (0.37) | SIRT1SIRT2EPHX1 | |
| SCHEMBL327667 | 0.73 | SIRT1 (0.36) | SIRT1CA1CA2SIRT2SIRT3 | |
| SCHEMBL13401550 | 0.72 | — | — | |
| SCHEMBL14542727 | 0.72 | AKT1 (0.36) | SIRT1SIRT2SIRT5 | |
| SCHEMBL10066896 | 0.71 | CPB1 (0.32) | SIRT1CA1CA2SIRT2SIRT5 | |
| SCHEMBL11964062 | 0.69 | AKT1 (0.42) | SIRT1CA1CA2SIRT2SIRT3 | |
| SCHEMBL14445101 | 0.69 | TGM2 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100092483-A1 | Compositions monovalent for CD40L binding and methods of use | DOMANTIS LIMITED | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100092483-A1 | Compositions monovalent for CD40L binding and methods of use | CD40LG, CD40, FCGR1A | SIRT1 2017/4885CA1 4301/4885CA2 4303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.